Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

334 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Interleukin-31 promotes fibrosis and T helper 2 polarization in systemic sclerosis.
Kuzumi A, Yoshizaki A, Matsuda KM, Kotani H, Norimatsu Y, Fukayama M, Ebata S, Fukasawa T, Yoshizaki-Ogawa A, Asano Y, Morikawa K, Kazoe Y, Mawatari K, Kitamori T, Sato S. Kuzumi A, et al. Among authors: fukasawa t. Nat Commun. 2021 Oct 12;12(1):5947. doi: 10.1038/s41467-021-26099-w. Nat Commun. 2021. PMID: 34642338 Free PMC article.
Nucleosome in patients with systemic sclerosis: possible association with immunological abnormalities via abnormal activation of T and B cells.
Yoshizaki A, Taniguchi T, Saigusa R, Fukasawa T, Ebata S, Numajiri H, Nakamura K, Yamashita T, Takahashi T, Toyama T, Asano Y, Tedder TF, Sato S. Yoshizaki A, et al. Among authors: fukasawa t. Ann Rheum Dis. 2016 Oct;75(10):1858-65. doi: 10.1136/annrheumdis-2015-207405. Epub 2015 Nov 13. Ann Rheum Dis. 2016. PMID: 26567180
Unprecedented success of rituximab therapy for prednisolone- and immunosuppressant-resistant systemic sclerosis-associated interstitial lung disease.
Ebata S, Yoshizaki A, Fukasawa T, Nakamura K, Yamashita T, Miura S, Saigusa R, Ichimura Y, Takahashi T, Hirabayashi M, Taniguchi T, Akamata K, Asano Y, Sato S. Ebata S, et al. Among authors: fukasawa t. Scand J Rheumatol. 2017 May;46(3):247-252. doi: 10.1080/03009742.2016.1231341. Epub 2016 Nov 30. Scand J Rheumatol. 2017. PMID: 27900875 No abstract available.
Contribution of Soluble Forms of Programmed Death 1 and Programmed Death Ligand 2 to Disease Severity and Progression in Systemic Sclerosis.
Fukasawa T, Yoshizaki A, Ebata S, Nakamura K, Saigusa R, Miura S, Yamashita T, Hirabayashi M, Ichimura Y, Taniguchi T, Asano Y, Shimizu H, Kazoe Y, Mawatari K, Kitamori T, Sato S. Fukasawa T, et al. Arthritis Rheumatol. 2017 Sep;69(9):1879-1890. doi: 10.1002/art.40164. Epub 2017 Aug 1. Arthritis Rheumatol. 2017. PMID: 28556548
Exacerbated Immune Complex-Mediated Vascular Injury in Mice with Heterozygous Deficiency of Aryl Hydrocarbon Receptor through Upregulation of Fcγ Receptor III Expression on Macrophages.
Nakajima R, Miyagaki T, Morimura S, Fukasawa T, Oka T, Yoshizaki A, Sugaya M, Sato S. Nakajima R, et al. Among authors: fukasawa t. J Invest Dermatol. 2018 Oct;138(10):2195-2204. doi: 10.1016/j.jid.2018.03.1520. Epub 2018 Mar 30. J Invest Dermatol. 2018. PMID: 29605671 Free article.
Rapid alteration of serum interleukin-6 levels may predict the reactivity of i.v. cyclophosphamide pulse therapy in systemic sclerosis-associated interstitial lung disease.
Numajiri H, Yoshizaki A, Fukasawa T, Ebata S, Nakamura K, Yamashita T, Saigusa R, Miura S, Hirabayashi M, Yoshizaki A, Sumida H, Asano Y, Kazoe Y, Mawatari K, Kitamori T, Sato S. Numajiri H, et al. Among authors: fukasawa t. J Dermatol. 2018 Oct;45(10):1221-1224. doi: 10.1111/1346-8138.14580. Epub 2018 Jul 27. J Dermatol. 2018. PMID: 30051925
334 results